Industry & Policy News

[Entrada Therapeutics, Inc. (] Entrada Therapeutics, Inc. announced a new collaboration with the Myotonic Dystrophy Clinical Research Network supporting Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1.

[ScienceInsider] A decision by the Southwest National Primate Research Center to retain its director with full duties despite a finding that he engaged in research misconduct has sparked disbelief.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash.

[Sanofi] Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. This strategic partnership demonstrates Sanofi and Innovent’s commitment to bringing high quality oncology medicines to patients in China.

[InterVenn^® Biosciences (Business Wire, Inc.)] InterVenn® Biosciences announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.

[CymaBay Therapeutics, Inc.] CymaBay Therapeutics, Inc. announced the completion of enrollment for RESPONSE, a global Phase III study evaluating seladelpar for patients with Primary Biliary Cholangitis.